Martin Madsen

Appearances

HEPATOPROTECTIVE EFFECTS OF SEMAGLUTIDE IN THE GAN DIET-INDUCED OBESE AND BIOPSY-CONFIRMED MOUSE MODEL OF NASH WITH ADVANCED FIBROSIS AND HEPATOCELLULAR CARCINOMA
Date
May 8, 2023
BACKGROUND: The glucagon-like-receptor (GLP)-1 agonist semaglutide has demonstrated therapeutic efficacy on clinical endpoints in a recent phase 2 clinical trial in patients with non-alcoholic steatohepatitis (NASH)(Newsome et al. NEJM, 2021)…
Presenter
Sebastian Møller Nguyen Heimbürger
Speakers
Malte Nielsen
Mathias Bonde Møllerhøj
Denise Oró
Martin Madsen
Mogens Vyberg
Henrik Hansen
Michael Feigh